Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.84 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.73 |
| ▸ | IGF1R | P08069 | 5/20 | 0.73 |
| ▸ | EGFR | P00533 | 4/20 | 0.73 |
| ▸ | PLK4 | O00444 | 2/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.73 |
| ▸ | AURKA | O14965 | 2/20 | 0.73 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.73 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.73 |
| ▸ | JAK2 | O60674 | 2/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.73 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.73 |
| ▸ | PAK4 | O96013 | 2/20 | 0.73 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.73 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | FYN | P06241 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911991 | 0.92 | ULK1 (0.72) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL12892789 | 0.92 | ULK1 (0.71) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL375608 | 0.91 | ULK1 (1.00) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL29900883 | 0.91 | ULK1 (1.00) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL30123962 | 0.91 | EGFR (0.77) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL26451583 | 0.91 | EGFR (0.77) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL13394913 | 0.90 | ALK (0.74) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL4094604 | 0.88 | ALK (0.72) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL12781002 | 0.88 | ULK1 (0.77) | ULK1ALKIGF1REGFRPLK4 | |
| SCHEMBL12892811 | 0.87 | ULK1 (0.67) | ULK1ALKIGF1REGFRPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150184161-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2015-07-02 | — | — | US | claimed |
| EP-2116553-B1 | EML4-ALK fusion gene | ASTELLAS PHARMA INC (JP) | 2014-07-30 | — | — | EP | claimed |
| US-20130158095-A1 | EML4-ALK FUSION GENE | CUREGENE K.K. (JP) | 2013-06-20 | — | — | US | claimed |
| US-20110230545-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | claimed |
| US-20100240673-A1 | EML4-ALK Fusion Gene | ASTELLAS PHARMA INC. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2116553-A1 | EML4-ALK fusion gene | Astellas Pharma Inc. (JP) | 2009-11-11 | — | — | EP | claimed |
| US-20090099193-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2009-04-16 | — | — | US | claimed |
| EP-1914240-A1 | EML4-ALK fusion gene | Astellas Pharma Inc. (JP) | 2008-04-23 | — | — | EP | claimed |
| US-20080090776-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2008-04-17 | — | — | US | claimed |
| EP-4537844-A1 | PROPHYLACTIC OR THERAPEUTIC AGAINST EXACERBATION OR RECURRENCE OF CANCER, AND SCREENING METHOD THEREFOR | Keio University (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119604307-A | Preventive or therapeutic agent for recurrence or recurrence of cancer and screening method therefor | 庆应义塾 | 2025-03-11 | — | — | CN | disclosed |
| WO-2023238939-A1 | PROPHYLACTIC OR THERAPEUTIC AGAINST EXACERBATION OR RECURRENCE OF CANCER, AND SCREENING METHOD THEREFOR | 慶應義塾 | 2023-12-14 | — | — | WO | disclosed |
| US-20220003771-A1 | METHODS OF DETECTING A POLYPEPTIDE HAVING ANAPLASTIC LYMPHOMA KINASE ACTIVITY IN KIDNEY CANCER | CELL SIGNALING TECHNOLOGY, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20200363417-A1 | METHODS OF DETECTING A POLYPEPTIDE HAVING ANAPLASTIC LYMPHOMA KINASE ACTIVITY IN KIDNEY CANCER | CELL SIGNALING TECHNOLOGY, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-1914240-B1 | EML4-ALK fusion gene | ASTELLAS PHARMA INC (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-7605131-B2 | EML4-ALK fusion gene | ASTELLAS PHARMA INC. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090099193-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2009-04-16 | — | — | US | disclosed |
| EP-1914240-A1 | EML4-ALK fusion gene | Astellas Pharma Inc. (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090776-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2008-04-17 | — | — | US | disclosed |